Pathological Processes Clinical Trial
Official title:
An Open-Label, Multicenter, Phase 4 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark(R) in Pediatric Patients (2-11 & 12-18 Yrs) Referred for Contrast-Enhanced MRI
The objective of this study is to characterize the safety, efficacy and pharmacokinetic profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient population.
Pediatric patients referred for magnetic resonance imaging (MRI) of the liver or central nervous system (CNS) will be stratified by age to one of two groups (2 through 11 and 12 through 18 years of age). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04073290 -
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
|
Phase 4 | |
Recruiting |
NCT02681913 -
Adenosine as an Adjunct to Blood Cardioplegia
|
Phase 2 | |
Terminated |
NCT00527670 -
Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias
|
N/A |